WNK2 and cancer: The dysregulation of ERK, a member of the mitogen-activated protein kinase (MAPK) family, and AKT signaling has been implicated in a wide range of cancers, where the cross-talk between the PI3K/AKT and MAPK/ERK pathways has been associated with drug resistance59.